Program Overview

Locus' internal development programs, derived from its technology, are focused on oral drug therapies that address major unmet medical needs, principally in cancer and inflammation. Locus is currently completing a Phase I study with LP-261, Locus' lead oral oncology compound. In its inflammation program, Locus has created uniquely selective allosteric p38 inhibitors that may offer an improved safety profile compared to other p38 compounds under development. LP-590, a multi-kinase inhibitor, is targeted for development in oncology and ocular disease. Other earlier stage projects include an Hsp90 program with the National Cancer Institute (NCI), an EPO receptor antagonist for ocular and renal cancer with the National Institute of Health (NIH) and a gp41 program for AIDS/HIV in association with the International Partnership of Microbicides (IPM).